血管疾病患者的钠摄入量与房颤发生
该队列研究纳入ONTARGET和TRANSCEND两项多中心随机临床试验中27 391例有血管疾病或高危糖尿病且无房颤史的参与者,通过晨尿Kawasaki公式估算钠摄入量。平均随访4.6年,1562例(5.7%)发生房颤。多变量调整后,钠摄入量与房颤风险呈J型关联(非线性P=0.03),钠摄入≥8 g/d者(占3%)相比4~5.99 g/d者房颤风险增加(HR 1.32,95%CI 1.01~1.74);钠摄入>6 g/d者(占19%)每增加1 g/d,房颤风险增加10%(HR 1.10,95%CI 1.03~1.18),而较低钠摄入水平未见房颤风险进一步降低。作者认为,降低钠摄入以预防房颤应针对高钠饮食人群。
要点
- 在血管疾病或高危糖尿病患者中,钠摄入量与房颤风险呈J型关联(非线性P=0.03)。
- 钠摄入≥8 g/d者(占3%)相比4~5.99 g/d者,房颤风险增加(HR 1.32,95%CI 1.01~1.74)。
- 钠摄入>6 g/d者(占19%)每增加1 g/d,房颤风险增加10%(HR 1.10,95%CI 1.03~1.18)。
- 较低钠摄入水平未见房颤风险进一步降低。
适用人群与场景
- 纳入:ONTARGET和TRANSCEND试验中有血管疾病或高危糖尿病的参与者,且有晨尿样本用于钠测量、关键协变量数据完整、无房颤病史、入组后第一年未检出房颤。
- 排除:无尿样本用于钠测量、关键协变量数据缺失、有房颤病史、入组后第一年检出房颤的参与者。
研究设计与关键结果
- 研究类型:基于ONTARGET和TRANSCEND两项多中心随机临床试验的队列研究,共纳入27 391例参与者(平均[SD]年龄66.3[7.2]岁;19 310例[70.5%]男性)。
- 暴露:通过晨尿Kawasaki公式估算钠摄入量,平均(SD)估算钠摄入量为4.8(1.6)g/d。
- 主要终点:平均(SD)随访4.6(1.0)年期间,1562例(5.7%)发生房颤。
- 多变量调整后,钠摄入量与房颤风险呈J型关联(非线性P=0.03)。
- 与钠摄入4~5.99 g/d相比,钠摄入≥8 g/d(占3%的参与者)与房颤发生相关(HR 1.32,95%CI 1.01~1.74)。
- 立方样条显示,钠摄入>6 g/d(占19%的参与者)时,每增加1 g/d钠摄入,房颤风险增加10%(HR 1.10,95%CI 1.03~1.18),但在较低钠摄入水平未见房颤风险进一步降低。
证据类型、等级与局限
- 证据类型:基于两项多中心随机临床试验的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,降低钠摄入以预防房颤应针对高钠饮食人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Numerous prospective cohort studies have reported a J-shaped association of urinary sodium excretion with cardiovascular events and mortality.
OBJECTIVE: To study the association between sodium intake and incident atrial fibrillation (AF).
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included participants in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomised Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) multicenter, randomized clinical trials comparing the effect of ramipril 10 mg daily with telmisartan 80 mg daily, or their combination (ONTARGET) or 80 mg telmisartan daily with placebo (TRANSCEND) for the outcome of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. ONTARGET and TRANSCEND included 31 546 participants with vascular disease or high-risk diabetes, and this study excluded participants without a urine sample for sodium measurement, missing data for key covariates, a history of AF, or AF detected in the first year after enrollment. Analyses were performed in July 2023 to May 2024.
EXPOSURE: Estimated sodium intake from a morning fasting urine sample (Kawasaki formula).
MAIN OUTCOMES AND MEASURES: The main outcome was incident AF. The association between estimated sodium intake and incident AF was modeled using multivariable adjusted Cox regression and cubic splines.
RESULTS: A total of 27 391 participants (mean [SD] age, 66.3 [7.2] years; 19 310 [70.5%] male) were included. Mean (SD) estimated sodium intake was 4.8 (1.6) g/d. During a mean (SD) follow-up of 4.6 (1.0) years, 1562 participants (5.7%) had incident AF. After multivariable adjustment, a J-shaped association between sodium intake and AF risk was observed (P for nonlinearity = .03). Sodium intake of 8 g/d or greater (3% of participants) was associated with incident AF (hazard ratio, 1.32; 95% CI, 1.01-1.74) compared with sodium intake of 4 to 5.99 g/d. Cubic splines showed that sodium intake greater than 6 g/d (19% of participants) was associated with a 10% increased AF risk per additional 1-g/d sodium intake (hazard ratio, 1.10; 95% CI, 1.03-1.18), but with no further lowering of AF risk at lower levels of sodium intake.
CONCLUSIONS AND RELEVANCE: In this cohort study of sodium intake and AF risk, there was a J-shaped association between sodium intakes and AF risk in patients with cardiovascular disease or diabetes. Lowering sodium intake for AF prevention is best targeted at individuals who consume high sodium diets.
参考来源
- Johnson LS, Mente A, Joseph P, et al. Sodium Intake and Incident Atrial Fibrillation in Individuals With Vascular Disease. JAMA Netw Open. 2024. PMID: 38990569. doi:10.1001/jamanetworkopen.2024.21589
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。